Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 4Tumor Positron-Emission Tomography 1Rectal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lung Neoplasms 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1177Lu-EB-FAPI 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × 68Ga-FAPI × Clear all
NCT07553741 2026-04-28

Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase NA Completed
27 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡